

Time	Friday, February 17th						
	1F 102 (200)	2F, 201 ABC (400)	2F, 201DEF (400)	3F Plenary Hall (1200)	3F North Lounge (90)	3F South Lounge (90)	4F, VIP Room (250)
08:00-09:00	Meet the expert 1	Meet the expert 2			Meet the expert 3	AARC	Meet the expert 4
	Surveillance of HCC in Patients With HCV after SVR: Who and How?	Checkpoint Inhibitor-induced Immune-mediated Hepatitis			How should we Manage NASH Patients with Cardiometabolic Disease?	Session 1: Optimizing the survival of a patient with ACLF (08:00-09:20)	Beta Blockers in Patients with Cirrhosis and Portal Hypertension: When and How?
09:00-09:30				Plenary Lecture 1 Scott L. Friedman		AARC	
09:30-10:00				Plenary Lecture 2 Chien-Jen Chen		Session 2: Optimizing the transplant free survival (09:25-10:55)	
10:00-10:20	Break / Poster & Exhibition						
10:20-12:00	APASL Symposium 13	APASL Symposium 14	APASL Symposium 15	State-of-the-Art Lecture 7 Vijay H. Shah	Free Paper 7	AARC	APASL Symposium 16
	Liver Diseases in Pregnancy and Children	HCV: Strategy to Eliminate HCV Infection	HCC/CC: Epidemiology, Natural History, Diagnosis, and Staging	State-of-the-Art Lecture 8 Naoko Ohtani	other infection in liver and MAFLD (basic) 1. Chun-Ying Wu 2. Vincent Wai-Sun Wong	Session 3: Perioperative care of ACLF (11:00-12:30)	Viral Hepatitis Other Than HBV and HCV
				State-of-the-Art Lecture 9 Jordi Gracia-Sancho			
12:00-13:30		Satellite Symposium 6 Gilead	Satellite Symposium 7		Satellite Symposium 8 GSK		Satellite Symposium 9 Grifols
13:40-15:20	APASL Symposium 17	APASL Symposium 18	APASL Symposium 19	State-of-the-Art Lecture 10 Zhigang Tian	Free Paper 8	AARC	APASL Symposium 20
	Nutrition and Sarcopenia in Liver Diseases	HCV: Basic Research: Virology and Immunology	HCC/CC: Surgery and Locoregional Therapy	State-of-the-Art Lecture 11. Ann-Lii Cheng	HBV (clinical) 1. Heiner Wedemeyer 2. Tai-Tsung Tseng	Session 4: Post-LT management of ACLF (13:30-14:45)	Alcohol Related Liver Disease (ALD) and Drug Induced Liver Injury (DILI)
				State-of-the-Art Lecture 12 Yen-Hsuan Ni		Session 5: Clinical case Scenarios of LT in ACLF (14:50-16:20)	
15:20-15:50	Break / Poster & Exhibition						
15:50-17:30	APASL Symposium 21	APASL Symposium 22	APASL Symposium 23	Joint Symposium 1	Free Paper 9	AARC	APASL Symposium 24
	Multi-Omics and Liver	HCV: Natural History and Current Therapy (Including Special Populations)	HCC/CC: Systemic Therapy Including Early Phase Data for Novel Treatments in Cholangiocarcinoma (15:50-17:05)	EASL-APASL	cirrhosis and ACLF 1. Yasuko Iwakiri 2. Moon-Young Kim	Session 6: Consensus statement of LDLT in ACLF (16:30-17:00)	Special Issues in Asia-Pacific Region (15:50-17:55)
						Future Vision of AARC (17:00-17:20)	
17:30-18:00	Break / Poster & Exhibition						
18:30-21:00	Gala Dinner						

Friday, February 17<sup>th</sup>

Registration

1F lobby

07:30

Meet the Expert 1

Room 102

08:00-09:00

Time	No.	Name	City	Topic
08:00-9:00		Ming-Lung Yu	Kaohsiung	Surveillance of HCC in Patients with HCV after SVR: Who and How?
08:00-9:00		Pierre Nahon	Paris	Surveillance of HCC in Patients with HCV after SVR: Who and How?

Meet the expert 2

Room 201ABC

08:00-09:00

Time	No.	Name	City	Topic
08:00-09:00		Stephen Lam Chan	Hong Kong	Checkpoint Inhibitor-Induced Immune-Mediated Hepatitis
08:00-09:00		Chih-Hung Hsu	Taipei	Checkpoint Inhibitor-Induced Immune-Mediated Hepatitis

Meet the Expert 3

North Lounge

08:00-09:00

Time	No.	Name	City	Topic
08:00-09:00		Vincent Wai-Sun Wong	Hong Kong	How Should We Manage Nash Patients with Cardiometabolic Disease?
08:00-09:00		Jee-Fu Huang	Kaohsiung	How Should We Manage Nash Patients with Cardiometabolic Disease?

Meet the Expert 4

VIP Room

08:00-09:00

Time	No.	Name	City	Topic
------	-----	------	------	-------

08:00-09:00	Hui-Chun Huang	Taipei	Beta Blockers in Patients with Cirrhosis and Portal Hypertension: When and How?
08:00-09:00	Richard Moreau	Paris	Beta Blockers in Patients with Cirrhosis and Portal Hypertension: When and How?

#### AARC Session 1: Optimizing the Survival of a Patient with ACLF

South Lounge

08:00-09:20

Time	No.	Name	City	Topic
08:00-08:10		Han-Chieh Lin		Welcome and Concept of Collaborative Studies in APASL
08:10-08:20	Moderator	Masao Omata	Tokyo	ACLF in 2023- Where Are We 15 Years Later
08:10-08:20		Shiv Kumar Sarin		ACLF in 2023- Where Are We 15 Years Later
08:20-08:35	Moderator	Richard Moreau		Managing Acute Precipitant of ACLF
08:20-08:35		Grace Lai-Hung Wong		Managing Acute Precipitant of ACLF
08:35-08:50	Moderator	Hasmik Ghazinyan		Managing Steroid Non-Response Without LT in Alcohol Associated ACLF
08:35-08:50		Vijay H. Shah		Managing Steroid Non-Response Without LT in Alcohol Associated ACLF
08:50-09:05	Moderator	Kadir Dockmechi		Reversibility of ACLF
08:50-09:05		Ashok Choudhury		Reversibility of ACLF
09:05-09:20	Moderator	Dong Joon Kim		ACLF: Is Primary Prevention Possible
09:05-09:20		Naoko Ohtani		ACLF: Is Primary Prevention Possible

#### Plenary Lecture 1

Plenary Hall

09:00-09:30

Moderator Pei-Jer Chen (Taipei)

Time	No.	Name	City	Topic
09:00-09:30		Scott L. Friedman	New York	Evolving Challenges in Hepatic Fibrosis

## AARC Session 2: Optimizing the Transplant Free Survival

South Lounge

09:25-10:55

Time	No.	Name	City	Topic
09:25-09:40	Moderator	Gamal Shiha		Infections and Prophylaxis in ACLF and Their Implications on Transplantation
09:25-09:40		Qing Ning		Infections and Prophylaxis in ACLF and Their Implications on Transplantation
09:40-09:55	Moderator	Jennifer C. Lai		Defining Futility in ACLF/Palliation in ACLF
09:40-09:55		Jin Hua Hua		Defining Futility in ACLF/Palliation in ACLF
09:55-10:10	Moderator	Manoj Sharma		Organ Support in ACLF
09:55-10:10		Ming-Lung Yu		Organ Support in ACLF
10:10-10:25	Moderator	Young-Suk Lim		Protocolized Nutrition in ACLF: Pre-Peri--Post Operative
10:10-10:25		David E. Cohen		Protocolized Nutrition in ACLF: Pre-Peri--Post Operative
10:25-10:40	Moderator	Mazen Nouredin		Regenerative and Cell Based Therapy in ACLF: What, When and How?
10:25-10:40		Stuart Forbes		Regenerative and Cell Based Therapy in ACLF: What, When and How?
10:40-10:55	Moderator	Chien-Hung Chen		Management of Ascites, Hyponatremia and AKI in ACLF
10:40-10:55		Sombat		Management of Ascites, Hyponatremia and AKI in ACLF

## Plenary Lecture 2

Plenary Hall

09:30-10:00

Moderator Shiv Kumar Sarin (New Delhi)

Time	No.	Name	City	Topic
09:30-10:00		Chien-Jen Chen	Taipei	International Collaboration and Paradigm Shift in Hepatology: Precision Health and Innovation

## APASL Symposium 13-Liver Diseases in Pregnancy and Children

Room 102

10:20-12:00

Moderator Huey-Ling Chen (Taipei)/Winita Hardikar (Melbourne)

Time	No.	Name	City	Topic
10:20-10:45		Mei-Hwei Chang	Taipei	HBV Control: Starting Before Birth to Life-Long Care

10:45-11:10	Ka Wang Cheung	Hong Kong	Optimal Management of Pregnant Women with HBV Infection and Other Liver Diseases
11:10-11:35	Winita Hardikar	Melbourne	The Changing Landscape of Paediatric PSC
11:35-12:00	Ayano Inui	Kanagawa	Emerging Liver Diseases in Children: Keys to New Diagnosis and Treatment

#### APASL Symposium 14-HCV: Strategy to Eliminate HCV Infection

Room 201ABC

10:20-12:00

Moderator Sheng-Nan Lu (Kaohsiung)/Ming-Lung Yu (Kaohsiung)

Time	No.	Name	City	Topic
10:20-10:45		Benjamin Cowie	Melbourne	Interim Guidance for Country Validation of Viral Hepatitis Elimination
10:45-11:10		Chien-Jen Chen	Taipei	Taiwan's National Strategies and Actions Toward HCV Elimination Before 2025
11:10-11:35		Homie Razavi	Lafayette	Global Timing of Hepatitis C Virus Elimination in High-Income Countries.
11:35-12:00		Lindsey Hiebert	Boston	Retreatment of Chronic Hepatitis Infection: Real-World Regimens and Outcomes from National Treatment Programs in Three Low-And Middle-Income Countries.

#### APASL Symposium 15-HCC/CC: Epidemiology, Natural History, Diagnosis, and Staging

Room 201DEF

10:20-12:00

Moderator Po Chin Liang (Taipei)/Shiu-Feng Huang (Miaoli)

Time	No.	Name	City	Topic
10:20-10:45		Yasuni Nakanuma	Kanazawa	Pathologic Diagnosis of HCC/CC
10:45-11:10		Chih-Horng Wu	Taipei	Imaging Subclassification of Intrahepatic Cholangiocarcinoma: A Correlation with Pathological Findings and Clinical Outcome
11:10-11:35		Li-Tzong Chen	Kaohsiung	Precision Medicine (Genetic and Target Agents)
11:35-12:00		Po-Da Chen	Taipei	Long-Term Survival of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: A Nationwide Study

State-of-the-Art Lecture 7

Plenary Hall

10:20-10:50

Moderator Teerha Piratvisuth (Songkhla)

Time	No.	Name	City	Topic
17:00-17:30		Vijay H. Shah	Minnesota	The Digital Transformation of Hepatology

State-of-the-Art Lecture 8

Plenary Hall

10:55-11:25

Moderator Ming-Shiang Wu (Taipei)

Time	No.	Name	City	Topic
10:55-11:25		Naoko Ohtani	Osaka	Gut-Liver Axis-Mediated Mechanism of Liver Cancer

State-of-the-Art Lecture 9

Plenary Hall

11:30-12:00

Moderator Ying-Ying Yang (Taipei)

Time	No.	Name	City	Topic
11:30-12:00		Jordi Gracia-Sancho	Barcelona	Vascular Pathology and Liver Microcirculation in Cirrhotic Portal Hypertension

Free Paper 7: Other Infection in Liver and MAFLD (Basic)

North Lounge

10:20-12:00

Moderator Chun-Ying Wu / Vincent Wai-Sun Wong

APASL Symposium 16-Viral Hepatitis Other Than HBV and HCV

VIP Room

10:20-12:00

Moderator George V. Papatheodoridis (Athens)/Tsong-Hui Hu (Kaohsiung)

Time	No.	Name	City	Topic
10:20-10:45		Chien-Wei Su	Taipei	Epidemiology and Natural History of Hepatitis D
10:45-11:10		Heiner Wedemeyer	Hanover	Novel Treatment of Chronic Hepatitis D
11:10-11:35		Subrat Kumar Panda	New Delhi	Updates in Biology of HEV
11:35-12:00		Chien-Ching Hung	Taipei	HAV Infection in People Living With HIV

11:00-12:30

Time	No.	Name	City	Topic
11:00-11:15	Moderator	Sanjiv Saigal		Severity Scores in Listing and Determining Outcomes of LT
11:00-11:15		Mamta Bhat		Severity Scores in Listing and Determining Outcomes of LT
11:15-11:30	Moderator	Francis KL Chan		Donor Considerations in LDLT for ACLF
11:15-11:30		Viniyendra Pamecha		Donor Considerations in LDLT for ACLF
11:30-11:45	Moderator	Rinaldi Lesmana		Ideal Timing for Liver Transplant in ACLF
11:30-11:45		Jia ji Dong		Ideal Timing for Liver Transplant in ACLF
11:45-12:00	Moderator	J J Chun		Protocolized Nutrition in ACLF: Pre-peri--Post Operative
11:45-12:00		David E. Cohen		Protocolized Nutrition in ACLF: Pre-peri--Post Operative
12:00-12:15	Moderator	Tawaseek Tanwandi		Management of Ascites, Hyponatremia and AKI in ACLF
12:00-12:15		Sombat		Management of Ascites, Hyponatremia and AKI in ACLF
12:15-12:30	Moderator	Sen-Yung Hsieh		Recipient Considerations Including Recent Alcohol Intake
12:15-12:30		M Rela		Recipient Considerations Including Recent Alcohol Intake

## Satellite Symposium 6 Gilead

Room 201 ABC

12:00-13:30

## Satellite Symposium 7

Room 201 DEF

12:00-13:30

## Satellite Symposium 8 GSK

North Lounge

12:00-13:30

## Satellite Symposium 9 Grifols

VIP Room

12:00-13:30

AARC Session 4: Post-LT Management of ACLF

South Lounge

13:30-14:45

Time	No.	Name	City	Topic
13:30-13:45	Moderator	Diana Payawal		Surgical Considerations and Post-operative Care in ACLF
13:30-13:45		Korean Colleague/S G Lee		Surgical Considerations and Post-operative Care in ACLF
13:45-14:00	Moderator	Jasmohan S. Bajaj		Immunosuppression in ACLF Following LT: Is It Different?
13:45-14:00		George Lau		Immunosuppression in ACLF Following LT: Is It Different?
14:00-14:15	Moderator	Fasiha Kanwal		Metabolic Complications and Management Following LT
14:00-14:15		Soek-Siam Tan		Metabolic Complications and Management Following LT
14:15-14:30	Moderator	Chieu-Hao Huang		Long Term Outcomes of Patients with ACLF Following LT
14:15-14:30		Geoff McCaughan		Long Term Outcomes of Patients with ACLF Following LT
14:30-14:45	Moderator	Madunil A Niriella		Healthcare Utilization by ACLF Patients-is Survival the Only Benefit?
13:30-14:45		Mark Mutaiah		Healthcare Utilization by ACLF Patients-is Survival the Only Benefit?

Free Paper 8: HBV (Clinical)

North Lounge

13:40-15:20

Moderator Heiner Wedemeyer / Tai-Tsung Tseng

APASL Symposium 17-Nutrition and Sarcopenia in Liver Diseases

Room 102

13:40-15:20

Moderator Jin Mo Yang (Seoul)/Ying-Ying Yang (Taipei)

Time	No.	Name	City	Topic
13:40-14:05		Jennifer C. Lai	San Francisco	Malnutrition, Frailty, and Sarcopenia in Patients with Cirrhosis
14:05-14:30		Seung Up Kim	Seoul	Sarcopenia and Liver Fibrosis in Chronic Liver Diseases
14:30-14:55		Ching-Sheng Hsu	Chiayi	Sarcopenia in Hepatocellular Carcinoma



14:55-15:20	Chao-Wei Lee	Taoyuan	Skeletal Muscle and Body Fat Mass: Culprit for Poor HCC Outcome
-------------	--------------	---------	---

APASL Symposium 18-HCV: Basic Research: Virology and Immunology

Room 201ABC

13:40-15:20

Moderator Ming-Lung Yu (Kaohsiung)/Chun-Jen Liu (Taipei)

Time	No.	Name	City	Topic
13:40-14:05		Chun-Jen Liu	Taipei	Risk, Immune Remodeling and Prevention of HBV Reactivation Following HCV Clearance by DAA in HCV/HBV Dual Infection

14:05-14:30		Robert Thimme	Freiburg	T Cell Responses During HCV Infection and HCC
-------------	--	---------------	----------	---

14:30-14:55		Andrea Cox	Baltimore	Oncogenic Potential After HCV Eradication
-------------	--	------------	-----------	---

14:55-15:20		Chien-Hao Huang	Taoyuan	The Parhogenic Role of Innate CD8+T Cells in Chronic Hepatitis C
-------------	--	-----------------	---------	--

APASL Symposium 19-HCC/CC: Surgery and Locoregional Therapy

Room 201DEF

13:40-15:20

Moderator Shi-Ming Lin (Taoyuan)/Kai-Wen Huang (Taipei)

Time	No.	Name	City	Topic
13:40-14:05		Chao-Long Chen	Kaohsiung	Evolving Strategies in LDLT for HCC

14:05-14:30		Shuichiro Shiina	Tokyo	Ablation for HCC: RFA, MWA, Cryo, IRE Update
-------------	--	------------------	-------	--

14:30-14:55		Ray Lee		Trans-Arterial Embolization with New Regimens for HCC
-------------	--	---------	--	---

14:55-15:20		Hee Chul Park	Seoul	Radiotherapy: Carbon and Proton Beam
-------------	--	---------------	-------	--------------------------------------

State-of-the-Art Lecture 10

Plenary Hall

13:40-14:10

Moderator Jaw-Ching Wu (Taipei)

Time	No.	Name	City	Topic
13:40-14:10		Zhigang Tian	Hefei	Breakdown of HBV-Immunotolerance and HCC Development

State-of-the-Art Lecture 11

Plenary Hall

14:15-14:45

Moderator Jean Charles Nault (Paris)

Time	No.	Name	City	Topic
14:15-14:45		Ann-Lii Cheng	Taipei	The Way We Will -- Guideline Harmonization

State-of-the-Art Lecture 12

Plenary Hall

14:50-15:20

Moderator George Lau (Hong Kong)

Time	No.	Name	City	Topic
14:50-15:20		Yen-Hsuan Ni	Taipei	Gut Microbiome Can Modulate the Immune Flare-Up in Chronic Hepatitis B

APASL Symposium 20-Alcohol Related Liver Disease (ALD) and Drug Induced Liver Injury (DILI)

VIP Room

13:40-15:20

Moderator Diana A. Payawal (Manila)/Jee-Fu Huang (Kaohsiung)

Time	No.	Name	City	Topic
13:40-14:05		Dong Joon Kim	Chuncheon	Alcoholic Related Liver Disease in Asia-Pacific
14:05-14:30		Gyongyi szabo	Boston	Gut-Liver Axis in Alcoholic Liver Disease
14:30-14:55		Yi-Shin Huang	Taipei	Update on Dili in Asia-Pacific
14:55-15:20		Shiu-Feng Huang	Miaoli	Pathologic Characteristics of Dili

AARC Session 5: Clinical Case Scenarios of LT in ACLF

South Lounge

14:50-16:20

Time	No.	Name	City	Topic
14:50-15:05	Moderator	Anand Shreshta		Case 1 ACLF in A Morbidly Obese ACLF with HBV Reactivation
14:50-15:05		Ajay Duseja		Case 1 ACLF in A Morbidly Obese ACLF with HBV Reactivation
15:05-15:20	Moderator	Anand Kulkarni		Case 2 ACLF- Alcohol with Recent Alcohol Intake

15:05-15:20		Akash Shukla	Case 2 ACLF- Alcohol with Recent Alcohol Intake
15:20-15:35	Moderator	Ulrich Beuers	Case 3 ACLF - AIH on High Dose Steroids
15:20-15:35		Vinod Arora	Case 3 ACLF - AIH on High Dose Steroids
15:35-15:50	Moderator	Atsushi Tanaka	Case 4 ACLF - ATT Induced DILI in ACLF; How to Transplant
15:35-15:50		Harshad Devarbhavi	Case 4 ACLF - ATT Induced DILI in ACLF; How to Transplant
15:50-16:05	Moderator	S.H. Han	Case 5 ACLF with Sepsis
15:50-16:05			Case 5 ACLF with Sepsis
16:05-16:20	Moderator	Oidov Baatarkhuu	Case 6 ACLF with Circulatory Failure
16:05-16:20		Jun Li	Case 6 ACLF with Circulatory Failure

#### APASL Symposium 21-Multi-Omics and Liver

Room 102

15:50-17:30

Moderator Hung-Chih Yang (Taipei)/Stephanie Ma (Hong Kong)

Time	No.	Name	City	Topic
15:50-16:15		Adil Mardinoglu	London	Application of Omics Technologies in the Study of Liver Disease
16:15-16:40		Hwai-i Yang	Taipei	Multiomics & Viral Hepatitis
16:40-17:05		Tetsuo Takehara	Osaka	Multiomics Approaches to MAFLD/NASH
17:05-17:30		Bin-Tean Teh	Singapore	Multiomics & Hepatocellular Carcinoma

#### APASL Symposium 22-HCV: Natural History and Current Therapy (Including Special Populations)

Room 201ABC

15:50-17:30

Moderator Mei-Hsuan Lee (Taipei)/Ray Kim (San Francisco)

Time	No.	Name	City	Topic
15:50-16:15		Fasiha Kanwal	Houston	Long-Term Benefits of Chronic Hepatitis C Patients After Sustained Virological Response
16:15-16:40		Eiichi Ogawa	Fukuoka	Predictors of Advanced Liver Disease of Chronic Hepatitis C Patients After Sustained Virological Response Following DAA Treatment

16:40-17:05	Chen-Hua Liu	Taipei	DAA Treatment in Hepatitis C Special Groups
17:05-17:30	Chia-Yen Dai	Kaohsiung	Unmet Needs in the Management of Chronic Hepatitis C for Elimination

APASL Symposium 23-HCC/CC: Systemic Therapy Including Early Phase Data for Novel Treatments in Cholangiocarcinoma

Room 201DEF

15:50-17:05				
Moderator	Masatoshi Kudo (Osaka)/Chiun Hsu (Taipei)			
Time	No.	Name	City	Topic
15:50-16:15		Takuji Okusaka	Tokyo	Cytotoxic Chemotherapy for Biliary Tract Cancers
16:15-16:40		Ming-Huang Chen	Taipei	Immunotherapy in Biliary Tract Cancer Update
16:40-17:05		Changhoon Yoo	Seoul	Translational Research for New Drug Development

Joint Symposium 1: EASL-APASL-Management of Hepatocellular Carcinoma: The East/West Point of Views

Plenary Hall

15:50-17:30				
Moderator	Jean Charles Nault (Paris) /Ann-Lii Cheng (Taipei)			
Time	No.	Name	City	Topic
15:50-16:15		Jean Charles Nault	Paris	Impact of Etiologies on HCC Biology and Implications for Future Biomarkers Guided Therapies
16:15-16:40		Valerie Chew	Singapore	Immune Microenvironment in HBV-Related HCC
16:40-17:05		Maria Reig	Barcelona	Systemic Treatments of HCC in Specific Populations (Comorbidities, Transplantation, Bleeding History, Uncontrolled Viral Infection...)
17:05-17:30		Stephen Lam Chan	Hong Kong	Systemic Therapy for Viral and Non-Viral HCC: From Asian Point of View

APASL Symposium 24-Special Issues in Asia-Pacific Region

VIP Room

15:50-17:55				
Moderator	Jose Sollano (Manila)/Pin-Nan Cheng (Tainan)			
Time	No.	Name	City	Topic
15:50-16:15		Banchob Sripa	Khon Kaen	Control of Liver Flukes in Southeast Asia and Impact on Risk of Cholangiocarcinoma

16:15-16:40	Harshad Devarbhavi	Bangalore	Herbal and Dietary Supplement Induced Liver Injury in Asia
16:40-17:05	Oidov Baatarkhuu	Ulan Bator	Mongolia's Experience and Strategies on Combating Common and Uncommon Liver Diseases in Asia
17:05-17:30	Satoshi Kobayashi	Kanazawa	Imaging Diagnosis of Vascular Diseases of the Liver in Asia-Pacific
17:30-17:55	Necati Örmeci	Istanbul	Hydatid Cyst in Asia-Pacific

#### AARC Session 6: Consensus Statement of LDLT in ACLF

South Lounge

16:30-17:00

Time	No.	Name	City	Topic
16:30-17:00		Jin Mo Yang		AARC Session 6: Consensus Statement of LDLT in ACLF

#### Future Vision of AARC

South Lounge

17:00-17:20

Time	No.	Name	City	Topic
17:00-17:20		Shiv Kumar Sarin		Future Vision of AARC

#### Free Paper 9: EASL-APASL

North Lounge

15:50-17:30

Moderator TBC

#### Break/Poster & Exhibition

17:30-18:00

#### Gala Dinner

18:30-21:00